MDM2 and MDMX promote ferroptosis by PPARα-mediated lipid remodeling

  1. Brent R. Stockwell1,8
  1. 1Department of Biological Sciences, Columbia University, New York, New York 10027, USA;
  2. 2Center for Drug Discovery, Department of Neurobiology, Duke University Medical Center, Durham, North Carolina 27710, USA;
  3. 3Department of Chemistry, University of California at Berkeley, Berkeley, California 94720, USA;
  4. 4Integrated Program in Cellular, Molecular, and Biomedical Studies, Columbia University, New York, New York 10032, USA;
  5. 5Helmholtz Zentrum München, Institute of Metabolism and Cell Death, Neuherberg 85764, Germany;
  6. 6Department of Molecular and Cell Biology, University of California at Berkeley, Berkeley, California 94720, USA;
  7. 7Department of Biochemistry and Molecular Genetics, University of Colorado Denver, Aurora, Colorado 80045, USA;
  8. 8Department of Chemistry, Columbia University, New York, New York 10027, USA
  1. Corresponding authors: clp3{at}columbia.edu,bstockwell{at}columbia.edu

Abstract

MDM2 and MDMX, negative regulators of the tumor suppressor p53, can work separately and as a heteromeric complex to restrain p53's functions. MDM2 also has pro-oncogenic roles in cells, tissues, and animals that are independent of p53. There is less information available about p53-independent roles of MDMX or the MDM2–MDMX complex. We found that MDM2 and MDMX facilitate ferroptosis in cells with or without p53. Using small molecules, RNA interference reagents, and mutant forms of MDMX, we found that MDM2 and MDMX, likely working in part as a complex, normally facilitate ferroptotic death. We observed that MDM2 and MDMX alter the lipid profile of cells to favor ferroptosis. Inhibition of MDM2 or MDMX leads to increased levels of FSP1 protein and a consequent increase in the levels of coenzyme Q10, an endogenous lipophilic antioxidant. This suggests that MDM2 and MDMX normally prevent cells from mounting an adequate defense against lipid peroxidation and thereby promote ferroptosis. Moreover, we found that PPARα activity is essential for MDM2 and MDMX to promote ferroptosis, suggesting that the MDM2–MDMX complex regulates lipids through altering PPARα activity. These findings reveal the complexity of cellular responses to MDM2 and MDMX and suggest that MDM2–MDMX inhibition might be useful for preventing degenerative diseases involving ferroptosis. Furthermore, they suggest that MDM2/MDMX amplification may predict sensitivity of some cancers to ferroptosis inducers.

Keywords

Footnotes

  • Received October 25, 2019.
  • Accepted January 21, 2020.

This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issue publication date (see http://genesdev.cshlp.org/site/misc/terms.xhtml). After six months, it is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at http://creativecommons.org/licenses/by-nc/4.0/.

| Table of Contents

Life Science Alliance